BridgeBio Pharma Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.61
Dividend & YieldN/A$ (N/A)
Beta 0.59
Market capitalization 1.3B
Operating cash flow -460.15M
ESG Scores unknown

Company description

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Sector: Healthcare - Industry: Biotechnology

Financial Ratios
Quick Ratio6.58
Working Capital-0.75
Return On Equity0.65
Debt To Equity-1.96
Fixed Asset Ratio0.05
Fixed Interest Cover-12.26

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 16.7M -4.66M -735k 2.83M
Total Cashflows From Investing Activities -21.04M -217.25M -52.99M -200.83M
Net Borrowings 56.34M 36.94M 550M 1.08B
Total Cash From Financing Activities 501.55M 398.79M 447.19M 736.45M
Change To Operating Activities 5.79M -3.41M 12.82M 12.52M
Issuance Of Stock 95.98M 368.95M 14.13M 20.46M
Net Income -130.75M -260.59M -448.72M -562.54M
Change In Cash 343.87M -72.05M -5.52M 37.69M
Effect Of Exchange Rate
Total Cash From Operating Activities -136.64M -253.59M -399.71M -497.93M
Depreciation 859k 859k 1.46M 5.84M
Change To Account Receivables -2.85M -2.85M 2.85M -19.75M
Other Cashflows From Financing Activities 14.23M -7.09M -41.23M -158.95M
Change To Netincome -28.39M 17.06M 32.62M 63.16M
Capital Expenditures -2.18M -2.64M -7.52M -13.25M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 140.07M 209.95M 337.05M 451.02M
Income Before Tax -169.45M -288.58M -505.49M -586.45M
Net Income -130.75M -260.59M -448.72M -562.54M
Selling General Administrative 43.59M 94.35M 145.68M 188.91M
Gross Profit 38.06M 8.25M 66.6M
Ebit -183.66M -266.24M -474.48M -573.33M
Operating Income -183.66M -266.24M -474.48M -573.33M
Interest Expense -2.55M -8.77M -36.66M -46.78M
Income Tax Expense
Total Revenue 40.56M 8.25M 69.72M
Cost Of Revenue 2.5M 3.11M
Total Other Income ExpenseNet 14.21M -22.34M -31.01M -13.12M
Net Income From Continuing Ops -169.45M -288.58M -505.49M -586.45M
Net Income Applicable To Common Shares -130.75M -260.59M -448.72M -562.54M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 87.58M 155.7M 595.7M 1.88B
Total Stockholder Equity 314.88M 408.45M 57.91M -870.41M
Other Current Liabilities 4.01M 4.08M 9.55M 3.5M
Total Assets 464.94M 631.68M 703.59M 1.01B
Common Stock 92k 124k 125k 154k
Other Current Assets 139k 177k
Retained Earnings -179.44M -440.03M -888.75M -1.44B
Treasury Stock 254k -74.81M -275.13M
Cash 436.09M 363.77M 356.08M 393.77M
Total Current Liabilities 32.58M 60.38M 95.65M 135.07M
Other Stockholder Equity 254k 192k -132k
Property, Plant, and Equipment 1.57M 5.62M 36.83M 45.97M
Total Current Assets 445.22M 568.62M 642.82M 888.86M
Net Tangible Assets 314.88M 408.45M 57.91M -915.35M
Net Receivables 2.85M 19.75M
Accounts Payable 13.51M 8.85M 8.95M 11.88M


Insider Transactions

Here are the insider transactions of stock shares related to BridgeBio Pharma Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
KUMAR NEILSale at price 9.40 per share.D2022-11-17Chief Executive Officer34.64k
STEPHENSON BRIAN CSale at price 9.40 per share.D2022-11-17Chief Financial Officer19.68k
HOMCY CHARLES JD2022-11-16Director3.76k
SCHELLER RICHARD HD2022-11-16Director3.2k
KUMAR NEILD2022-11-16Chief Executive Officer68.71k
STEPHENSON BRIAN CD2022-11-16Chief Financial Officer30.47k
HOMCY CHARLES JD2022-08-16Director3.76k
SCHELLER RICHARD HD2022-08-16Director3.2k
KUMAR NEILD2022-08-16Chief Executive Officer68.7k
STEPHENSON BRIAN CD2022-08-16Chief Financial Officer26.68k
SCHELLER RICHARD HD2022-05-16Director3.19k
KUMAR NEILD2022-05-16Chief Executive Officer68.7k
STEPHENSON BRIAN CD2022-05-16Chief Financial Officer26.68k
HOMCY CHARLES JD2022-05-16Director3.76k
ELLIS ANDREAPurchase at price 8.39 per share.D2022-03-15Director12k
DACHILLE DOUGLAS A.Purchase at price 8.19 per share.I2022-03-14Director10k
KUMAR NEILD2022-02-16Chief Executive Officer7.52k
STEPHENSON BRIAN CD2022-02-16Chief Financial Officer2.49k
DACHILLE DOUGLAS A.Purchase at price 15.91 - 16.82 per share.I2022-01-05Director10k
DANIELS RONALD JPurchase at price 12.73 - 14.34 per share.D2021-12-30Director22.15k
LO ANDREW W.Purchase at price 12.90 - 14.30 per share.D2021-12-30Director7.5k
MOMTAZEE JAMES CPurchase at price 14.50 per share.D2021-12-29Director80k
SAUNDERS BRENTON LPurchase at price 14.48 per share.D2021-12-29Director17.6k
HASSAN FREDPurchase at price 14.17 per share.D2021-12-29Director19.3k
VALANTINE HANNAH A. M.D.Purchase at price 14.23 per share.D2021-12-29Director1.76k
DANIELS RONALD JSale at price 12.80 per share.D2021-12-28Director11.74k
KUMAR NEILD2021-11-16Chief Executive Officer7.52k
STEPHENSON BRIAN CD2021-11-16Chief Financial Officer2.49k
KUMAR NEILD2021-08-16Chief Executive Officer7.52k
STEPHENSON BRIAN CD2021-08-16Chief Financial Officer2.49k
SCHELLER RICHARD HSale at price 53.23 per share.D2021-08-04Officer and Director13.78k
SCHELLER RICHARD HConversion of Exercise of derivative security at price 17.00 per share.D2021-08-04Officer and Director13.78k
KUMAR NEILD2021-05-14Chief Executive Officer7.52k
STEPHENSON BRIAN CD2021-05-14Chief Financial Officer2.49k
HOMCY CHARLES JStock Award(Grant) at price 0.00 per share.D2021-03-01Director1.52k
SCOTT RANDAL WPurchase at price 62.50 per share.D2021-02-17Director16k
STEPHENSON BRIAN CPurchase at price 62.50 per share.D2021-02-17Chief Financial Officer8k
KKR GENETIC DISORDER L.P.Sale at price 60.47 per share.I2021-02-17Beneficial Owner of more than 10% of a Class of Security3.45M
KUMAR NEILD2021-02-16Chief Executive Officer5.13k
STEPHENSON BRIAN CD2021-02-16Chief Financial Officer1.71k
TURTLE CAMERONSale at price 69.34 - 69.94 per share.D2020-12-28Officer19.5k
TURTLE CAMERONConversion of Exercise of derivative security at price 0.16 - 17.00 per share.D2020-12-28Officer19.5k
SCHELLER RICHARD HSale at price 64.81 - 65.48 per share.D2020-12-21Officer and Director60.4k
SCHELLER RICHARD HSale at price 64.99 - 65.78 per share.D2020-12-18Officer and Director30k
SCHELLER RICHARD HSale at price 59.81 - 60.73 per share.D2020-12-15Officer and Director31.44k
SCHELLER RICHARD HConversion of Exercise of derivative security at price 17.00 per share.D2020-12-15Officer and Director29.28k
HENDERSON MICHAEL THOMASSale at price 51.12 - 51.69 per share.D2020-12-01Officer10k
HENDERSON MICHAEL THOMASConversion of Exercise of derivative security at price 1.05 per share.D2020-12-01Officer10k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to BridgeBio Pharma Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on BridgeBio Pharma Inc

Here is the result of two systematic investment strategies applied to BridgeBio Pharma Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on BridgeBio Pharma Inc

The following chart shows the equity curve of the two systematic investment strategies applied to BridgeBio Pharma Inc:

BridgeBio Pharma Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 14.03% on the backtest period.

Performance at glance

Performance

14.03 %

Latent gain

182.59 $

Invested capital

1301.69 $

Annualized return

5.61 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on BridgeBio Pharma Inc

This is the result of two momentum investment strategies applied to BridgeBio Pharma Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on BridgeBio Pharma Inc

The following chart shows all the entries opened by the momentum investment system on BridgeBio Pharma Inc:

BridgeBio Pharma Inc momentum entries
  • The first momentum investment strategy would give 52.18% of return on BridgeBio Pharma Inc. That represents 1329.84$ of latent gain with 2548.44$ of employed capital.
  • The second momentum investment strategy would give 32.86% of return on BridgeBio Pharma Inc. That represents 663.19$ of latent gain with 2018.09$ of employed capital.
Performance at glance (1Q Momentum)

Performance

52.18 %

Latent gain

1329.84 $

Invested capital

2548.44 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

32.86 %

Latent gain

663.19 $

Invested capital

2018.09 $

Annualized return

16.27 %

Momentum equity curve on BridgeBio Pharma Inc

The following chart shows the equity curve of the two momentum strategies applied to BridgeBio Pharma Inc:

BridgeBio Pharma Inc momentum equity

Note: the dividends potentially given by BridgeBio Pharma Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on BridgeBio Pharma Inc

The following chart shows the employed capital evolution of the two momentum strategies on BridgeBio Pharma Inc since the beginning:

BridgeBio Pharma Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on BridgeBio Pharma Inc

Buy the dip entry openings on BridgeBio Pharma Inc

BridgeBio Pharma Inc

The performance achieved by the robo-advisor on BridgeBio Pharma Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows BridgeBio Pharma Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of BridgeBio Pharma Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to BridgeBio Pharma Inc

The following chart shows the result of the investment strategy applied to BridgeBio Pharma Inc:

BridgeBio Pharma Inc

Note: the dividends potentially given by BridgeBio Pharma Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on BridgeBio Pharma Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on BridgeBio Pharma Inc:

BridgeBio Pharma Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on BridgeBio Pharma Inc

In this section, I will compare the three previous investment strategies applied to BridgeBio Pharma Inc.

Equity curve comparison on BridgeBio Pharma Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

BridgeBio Pharma Inc investment strategy comparison

Employed capital comparison on BridgeBio Pharma Inc

BridgeBio Pharma Inc investment comparison

Performance comparison on BridgeBio Pharma Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 14.03% 182.59$ 1301.69$ 5.61%
Momentum 1 quarter 52.18% 1329.84$ 2548.44$ 23.09%
Momentum 2 quarters 32.86% 663.19$ 2018.09$ 16.27%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

5.61 %

Momentum 1Q

16.27 %

Momentum 2Q

16.27 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with BridgeBio Pharma Inc:

Positive correlations

Most correlated stocks this year

  • BridgeBio Pharma Inc

  • Most correlated stocks last 3 months

  • Takung Art Co Ltd
  • STARHUB
  • BridgeBio Pharma Inc
  • BONDUELLE

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • T2 Biosystems Inc

  • Note: The algorithm computes the probability of correlation between BridgeBio Pharma Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of BridgeBio Pharma Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name BridgeBio Pharma Inc
    Country United States
    City Palo Alto
    Address 421 Kipling Street
    Phone 650 391 9740
    Website www.bridgebio.com
    FullTime employees 576
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker BBIO
    Market www.nasdaq.com

    BridgeBio Pharma Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown